IUSCC-0551; A Phase I/Ib Open Label Dose Finding Study to Evaluate Safety Pharmacodynamics and Efficacy of Pembrolizumab (MK-3475) in Combination with Vorinostat in Patients with Advanced Renal or Urothelial Cell Carcinoma

Study Overview

The purpose of this study is to determine the safety profile of combining two drugs, pembrolizumab and vorinostat, in bladder and kidney cancers.

Study Description

The purpose of this study is to determine the safety profile of combining two drugs, pembrolizumab and vorinostat, in bladder and kidney cancers.

Additional Information

Participants will not be paid for their participation.


  • IRB Number: 1510440598
  • Research Study Identifier: TX5640
  • Principal Investigator: Roberto Pili, MD

Recruitment Status

Open

Contact the research team to learn more about this study.

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

If you need assistance finding a study or if you have any questions, please email: ctsirro@iu.edu or call us at (317) 278-2176